blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2004181

EP2004181 - ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES [Right-click to bookmark this link]
StatusThe patent has been limited
Status updated on  21.04.2023
Database last updated on 10.03.2026
FormerNo opposition filed within time limit
Status updated on  30.12.2016
Most recent event   Tooltip21.04.2023(Expected) limited patent specificationpublished on 24.05.2023  [2023/21]
Applicant(s)For all designated states
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
[2023/21]
Former [2015/17]For all designated states
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
1111 Franklin Street, 12th Floor
Oakland CA 94607-5200 / US
Former [2008/52]For all designated states
The Regents of the University of California
Office of Technology Transfer 1111 Franklin Street, 12th Floor
Oakland CA 94607-5200 / US
Inventor(s)01 / JUNG, Michael, E.
UCLA Department of Chemistry & Biochemistry
Box 951569, 3505A Molecular Science Building
Los Angeles, CA 90095-1569 / US
02 / SAWYERS, Charles, L.
Sawyers Lab/HOPP
MSKCC
1275 York Avenue, Box 20
New York, NY 10021 / US
03 / OUK, Samedy
UCLA Department of Chemistry & Biochemistry
Box 951569, 3505A Molecular Science Building
Los Angeles, CA 90095-1569 / US
04 / TRAN, Chris
Sawyers Lab/HOPP
MSKCC
1275 York Avenue, Box 20
New York, NY 10021 / US
05 / WONGVIPAT, John
Sawyers Lab/HOPP
MSKCC
1275 York Avenue, Box 20
New York, NY 10021 / US
 [2016/08]
Former [2008/52]01 / JUNG, Michael, E.
UCLA Department of Chemistry & Biochemistry Box 951569, 3505A Molecular Science Building
Los Angeles, California 90095-1569 / US
02 / SAWYERS, Charles, L.
Sawyers Lab/HOPP MSKCC 1275 York Avenue, Box 20
New York, New York 10021 / US
03 / OUK, Samedy
UCLA Department of Chemistry & Biochemistry Box 951569, 3505A Molecular Science Building
Los Angeles, California 90095-1569 / US
04 / TRAN, Chris
Sawyers Lab/HOPP MSKCC 1275 York Avenue, Box 20
New York, New York 10021 / US
05 / WONGVIPAT, John
Sawyers Lab/HOPP MSKCC 1275 York Avenue, Box 20
New York, New York 10021 / US
Representative(s)Campbell, Patrick John Henry
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[2016/08]
Former [2008/52]Campbell, Patrick John Henry
J.A. Kemp & Co. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date07754060.727.03.2007
[2008/52]
WO2007US07485
Priority number, dateUS20060785978P27.03.2006         Original published format: US 785978 P
US20060833790P28.07.2006         Original published format: US 833790 P
[2008/52]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007126765
Date:08.11.2007
Language:EN
[2007/45]
Type: A2 Application without search report 
No.:EP2004181
Date:24.12.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 08.11.2007 takes the place of the publication of the European patent application.
[2008/52]
Type: B1 Patent specification 
No.:EP2004181
Date:24.02.2016
Language:EN
[2016/08]
Type: B3 Limited patent 
No.:EP2004181
Date:24.05.2023
Language:EN
[2023/21]
Search report(s)International search report - published on:US06.11.2008
(Supplementary) European search report - dispatched on:EP11.10.2010
ClassificationIPC:A61K31/4166, A61K31/4178, A61K31/4439, C07D233/86, C07D401/04
[2008/52]
CPC:
A61K31/4439 (EP,US); A61K9/48 (US); A61P13/08 (EP);
A61P15/08 (EP); A61P35/00 (EP); A61P43/00 (EP);
C07D401/04 (US); C07D405/04 (EP); C07D409/04 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/08]
Former [2008/52]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:ANDROGENREZEPTOR-MODULATOR ZUR BEHANDLUNG VON PROSTATAKREBS UND ANDROGENREZEPTOR-ASSOZIIERTE ERKRANKUNGEN[2008/52]
English:ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES[2008/52]
French:MODULATEUR DE RÉCEPTEUR ANDROGÈNE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE ET DE MALADIES ASSOCIÉES AU RÉCEPTEUR ANDROGÈNE[2008/52]
Entry into regional phase27.10.2008National basic fee paid 
27.10.2008Search fee paid 
27.10.2008Designation fee(s) paid 
27.10.2008Examination fee paid 
Examination procedure27.10.2008Examination requested  [2008/52]
27.04.2011Amendment by applicant (claims and/or description)
20.07.2011Despatch of a communication from the examining division (Time limit: M04)
25.11.2011Reply to a communication from the examining division
16.01.2014Despatch of a communication from the examining division (Time limit: M06)
23.07.2014Reply to a communication from the examining division
31.03.2015Communication of intention to grant the patent
05.08.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.09.2015Communication of intention to grant the patent
16.12.2015Fee for grant paid
16.12.2015Fee for publishing/printing paid
16.12.2015Receipt of the translation of the claim(s)
Divisional application(s)EP11163948.0  / EP2368550
EP13178047.0  / EP2656841
EP13178051.2  / EP2656842
EP16173574.1  / EP3100727
EP18181743.8  / EP3412290
EP21153358.3  / EP3835294
EP24159183.3
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.07.2011
Opposition(s)25.11.2016No opposition filed within time limit [2017/05]
Limitations:19.02.2021Date of receipt of request for limitation
 admissible
13.03.2023Communication of intention to limit the patent
14.04.2023Fee for printing patent specification after limitation
Fees paidRenewal fee
27.10.2008Renewal fee patent year 03
25.03.2010Renewal fee patent year 04
29.03.2011Renewal fee patent year 05
26.03.2012Renewal fee patent year 06
27.03.2013Renewal fee patent year 07
27.03.2014Renewal fee patent year 08
27.03.2015Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X] WO2005042488  (TAKEDA PHARMACEUTICAL et al.) [X] 1-15 * page 61, line 20; example 400; claim - * * page 24, line 12 * * page 36, paragraph 2 - page 37 *
 [X] WO0192253  (TANABE SEIYAKU CO et al.) [X] 1-15 * page 7, paragraph 4; example -; claim - *
 [X] US2003225138  (SIRCAR ILA et al.) [X] 1-15 * example -; claim - *
 [A] US5434176  (CLAUSSNER ANDRE et al.) [A] 1-15 * the whole document *
 [X] WO2004022572  (ALCHEMIA PTY LTD et al.) [X] 1-15 * pages 95,102; claim -; compounds 221,935,741 *
 [X] WO03032994  (BOEHRINGER INGELHEIM PHARMA et al.) [X] 1-15 * pages 25,51; claim -; compound 67 *
 [X] EP0770613  (GRUENENTHAL GMBH et al.) [X] 1-10 * example -; claim - *
 [X] WO0107048  (BOEHRINGER INGELHEIM PHARMA et al.) [X] 1-10 * example -; claim - *
 [X] US6350763  (KELLY TERENCE ALFRED et al.) [X] 1-10 * example -; claim - *
 [X] US5783707  (ELOKDAH HASSAN M et al.) [X] 1-10 * example 2; claim - *
 [X] US5554607  (ELOKDAH HASSAN M et al.) [X] 1-10 * example 3; claim - *
 [X] JPS59210083  (OTSUKA KAGAKU YAKUHIN et al.) [X] 1-10 * examples 1,2; claim -; table - *
 [X] WO0044731  (SEARLE & CO et al.) [X] 1-10 * page 152; example 20; claim - *
 [X] WO0026195  (SEARLE & CO et al.) [X] 1-10 * example 18; claim - *
 [X] WO2004111031  (NOVO NORDISK AS et al.) [X] 1-10 * example 5; claim - *
 [X] EP0144098  (SHIONOGI & CO et al.) [X] 1-10 * pages 60,70; claim - *
 [X] DE2614831  (BAYER AG et al.) [X] 1-10 * example 8; claim - *
 [X] JPS649978  (SHIONOGI & CO et al.) [X] 1-10 * claim -; table -; compound 86 *
 [E] WO2007045877  (KUDOS PHARM LTD et al.) [E] 1-10 * claim -; compounds 23,30 *
 [X]   ELOKDAH HASSAN ET AL: "Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM030219Z, vol. 47, no. 3, 29 January 2004 (2004-01-29), pages 681 - 695, XP002466516, ISSN: 0022-2623 [X] 1-10 * table 1; compounds 2,03 *

DOI:   http://dx.doi.org/10.1021/jm030219z
 [X]   DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 January 1974 (1974-01-01), DHAL, P. N. ET AL: "Synthesis of thiohydantoins, thiazolidones, and their derivatives from N1-(4'-arylthiazol-2'-yl)thioureas", XP002601019, retrieved from STN Database accession no. 1974:413424 [X] 1-6 * abstract *
 [X]   JOURNAL OF THE INDIAN CHEMICAL SOCIETY , 50(10), 680-4 CODEN: JICSAH; ISSN: 0019-4522, 1973
International search[X] WO03096980  (BRISTOL MYERS SQUIBB CO et al.) [X] 1, 5, 7-10, 12, 17-36
 [X] WO2005089752  (PTC THERAPEUTICS INC et al.) [X] 1, 7-9, 12, 17-36
 [X] WO2006010642  (AVENTIS PHARMA SA et al.) [X] 1, 2, 6-9, 12, 14, 15, 17-36
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.